LXEO · Lexeo Therapeutics Inc
United States · RS rating 4 · As of 2026-10-14
| Price | 2.63 USD |
|---|---|
| 1-day change | -4.0% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 4 / 7 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 6 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +18.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +75.3% |
| Market cap (USD) | $445.3M |